Onkologie. 2010:4(4):256-259

Medulloblastoma: the most common malignant brain tumor in children

Karel Zitterbart1, Zdeněk Pavelka1, Jana Zitterbartová2
1 Klinika dětské onkologie, LF MU a FN Brno
2 Klinika radiační onkologie, LF MU a Masarykův onkologický ústav, Brno

Medulloblastoma, an embryonal neuroectodermal tumor of the cerebellum, is the most common form of malignant brain tumor of childhood.

10–12 new cases occur in the Czech Republic each year. Current treatment, which combines modern techniques of neurosurgical

resection and radiotherapy, and adjuvant chemotherapy, has improved survival substantially. The intensity of multimodal therapy is based

on clinical criteria of age, metastatic disease and the extent of surgical resection. Nevertheless, 19–30 % of average risk and 30–70 % of

high risk patients experience relapses within 5 years from initial presentation. Identification of biological prognostic markers and cellular

targets will result in risk-adapted treatment, which is crucial for improving cure rates and reducing long-term sequelae.

Keywords: medulloblastoma, children, prognosis, radiotherapy, chemotherapy

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zitterbart K, Pavelka Z, Zitterbartová J. Medulloblastoma: the most common malignant brain tumor in children. Onkologie. 2010;4(4):256-259.
Download citation

References

  1. Bouffet E. Embryonal tumours of the central nervous system. Eur J Cancer 2002; 38: 1112-1120. Go to original source... Go to PubMed...
  2. Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994; 23: 458-464. Go to original source... Go to PubMed...
  3. Herrlinger U, Steinbrecher A, Rieger J, et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol 2005; 252: 291-299. Go to original source... Go to PubMed...
  4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. Go to original source... Go to PubMed...
  5. Reddy AT. Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol 2005; 75: 309-313. Go to original source... Go to PubMed...
  6. MacDonald TJ, Rood BR, Santi MR, et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 2003; 8: 174-186. Go to original source... Go to PubMed...
  7. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17: 832-845. Go to original source... Go to PubMed...
  8. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002; 94: 552-560. Go to original source... Go to PubMed...
  9. http://www.childrensoncologygroup.org/.
  10. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 1999; 17: 2127-2136. Go to original source... Go to PubMed...
  11. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202-4208. Go to original source... Go to PubMed...
  12. Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 2009; 23: 364-375. Go to original source... Go to PubMed...
  13. Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002; 49: 117-120. Go to PubMed...
  14. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-820. Go to original source... Go to PubMed...
  15. Feltl D, Cvek J. Klinická radiobiologie. 1. vydání. Havlíčkův Brod: Tobiáš, 2008.
  16. Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009; 27: 566-571. Go to original source... Go to PubMed...
  17. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352: 978-986. Go to original source... Go to PubMed...
  18. Halperin EC, Constine LS, Tarbell NJ, Kun LE. Pediatric Radiation Oncology. 4th edition. Philadelphia: Lippincott Williams & Wilkins, 2005.
  19. Massimino M, Gandola L, Spreafico F, et al. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys 2009; 73: 1358-1363. Go to original source... Go to PubMed...
  20. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 2006; 29: 308-313. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.